1 |
dpavlin |
1.1 |
<p><b>INTRODUCING A REFERENCE PRICE SYSTEM FOR PHARMACEUTICAL PRODUCTS IN CROATIA |
2 |
|
|
AND ITS INFLUENCE ON PLIVA'S BUSINESS PERFORMANCE </b></p> |
3 |
|
|
<p>Zagreb, 20 January 1999</p> |
4 |
|
|
<p> Prompted by the Ministry of Health, the Croatian Institute for Health Insurance |
5 |
|
|
("HZZO") has announced its intention to introduce, as of 01 February 1999, a |
6 |
|
|
system of so-called reference prices for all pharmaceutical products reimbursed |
7 |
|
|
by state health insurance. Accordingly, PLIVA d.d. ("PLIVA"), the largest pharmaceutical |
8 |
|
|
company in Croatia and leading pharmaceutical group in Central and Eastern Europe, |
9 |
|
|
has commenced negotiations with the Ministry of Health and HZZO about determining |
10 |
|
|
new prices of drugs.</p> |
11 |
|
|
<p> The reference price system is used in many European countries, and HZZO has |
12 |
|
|
embraced this model in order to reduce expenses in the Croatian health care |
13 |
|
|
system. This model will help HZZO save an estimated HRK 350 million annually. |
14 |
|
|
In terms of value, the introduction of these measures will mean approximately |
15 |
|
|
HRK 40 million less revenue for PLIVA annually from pharmaceutical sales on |
16 |
|
|
the Croatian market, where price reductions will mostly affect license products.</p> |
17 |
|
|
<p> Commenting on the decision of the Croatian Ministry of Health and the Croatian |
18 |
|
|
Institute for Health Insurance, Zeljko Covic, President of PLIVA's Management |
19 |
|
|
Board, stressed: </p> |
20 |
|
|
<p>"The problem of illiquidity in the Croatian health care system is one of the |
21 |
|
|
main reasons why HZZO has forced drug manufacturers to reduce their prices. |
22 |
|
|
This is an attempt to ration drug consumption in Croatia, that is, to reduce |
23 |
|
|
the proportion of it that health insurance subsidies. During negotiations with |
24 |
|
|
HZZO, PLIVA has showed understanding for the difficulties which exist in the |
25 |
|
|
health care system with two goals in mind: for regular collection of debts in |
26 |
|
|
the pharmaceutical industry to be achieved in Croatia, and to protect the vital |
27 |
|
|
interests of the company." </p> |
28 |
|
|
<p>For PLIVA, introducing the new system will cause an average 4-5% reduction |
29 |
|
|
in drug prices paid by state health insurance. Taking into consideration the |
30 |
|
|
fact that the total price reduction for products from HZZO's reference list |
31 |
|
|
will amount to, according to the HZZO information, an average 15%, PLIVA's products |
32 |
|
|
will have a smaller price reduction than those of other manufacturers. In order |
33 |
|
|
to decrease the negative effect that these price reductions could have on the |
34 |
|
|
company's financial results, PLIVA will exert its best efforts to reduce its |
35 |
|
|
costs with additional measures, primarily by further reducing its production |
36 |
|
|
costs and achieving more favourable contractual conditions with licence partners." |
37 |
|
|
</p> |